Skip to main content

Search

Reset all filters
958 Result(s)
Sort by

Boehringer Ingelheim Office Hours Video 2023

Boehringer Ingelheim Office Hours Video 2023

Boehringer Ingelheim’s Office Hours program provides mentoring and access to expertise to help early-stage companies advance their science.
Partnering with Boehringer Ingelheim

Partnering with Boehringer Ingelheim

Information on partnering with Boehringer Ingelheim including how the company enables new science, partnering interests and key facts on the R&D pipeline.
Boehringer Ingelheim Innovation Prize

Boehringer Ingelheim Innovation Prize

Find out more about how we’re providing valuable resources to life-science innovators to enable new and emerging science
Agreement-to-acquire-Labor-Dr.-Merk

Agreement-to-acquire-Labor-Dr.-Merk

Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
global-top-employer

global-top-employer

For the first time, Boehringer Ingelheim receives the award as a Global Top Employer as well as individual awards in 27 countries.
Candice is moving to Germany

Candice is moving to Germany

Are you considering a career at Boehringer Ingelheim? Find out why Candice loves working here. For more talent insights, visit our Careers Page.
Partnership-with-clicktherapeutics

Partnership-with-clicktherapeutics

Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia
Collaboration-with-OxfordBioTherapeutics

Collaboration-with-OxfordBioTherapeutics

Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
collaboration-LIBD

collaboration-LIBD

Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
Quality

Quality

At Boehringer Ingelheim, Quality is deeply embedded into the lifecycle of the product: from Research and development to the delivery to our patients.
Agreement-to-acquire-NBE-Therapeutics

Agreement-to-acquire-NBE-Therapeutics

Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
What we do

What we do

Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.